A bidirectional link between sulfatide and Alzheimer's disease

Area of Science:

• Neuroscience
• Biochemistry
• Molecular Biology

Background:

• Reduced sulfatide levels are observed in Alzheimer's disease (AD) patients.
• The interplay between amyloid precursor protein (APP) processing and sulfatide metabolism in AD pathogenesis is not fully understood.

Purpose of the Study:

• To elucidate the bidirectional regulatory relationship between APP processing and sulfatide synthesis.
• To investigate the therapeutic potential of modulating sulfatide levels in AD.

Main Methods:

• Utilized cell culture and transgenic mouse models with altered APP processing.
• Assessed the impact of APP intracellular domain (AICD) on Gal3st1/CST expression and sulfatide synthesis.
• Investigated the effect of sulfatide supplementation on amyloid-beta (Aβ) generation and secretase activity (BACE1, γ-secretase).
• Analyzed brain samples from AD patients and relevant animal models.

Main Results:

• APP intracellular domain (AICD) was found to decrease Gal3st1/CST expression, leading to reduced sulfatide synthesis.
• Sulfatide supplementation decreased Aβ generation by inhibiting BACE1 and γ-secretase activity.
• Reduced BACE1 levels were linked to increased lysosomal degradation, while reduced γ-secretase activity resulted from direct effects and altered component levels in lipid rafts.
• Deficiency in arylsulfatase A or Gal3st1/CST mirrored these changes.
• Sulfatides reduced γ-secretase activity in AD patient brain homogenates.
• A negative correlation was observed between human brain APP levels and GAL3ST1/CST expression.

Conclusions:

• A critical feedback loop exists between APP processing and sulfatide homeostasis in Alzheimer's disease.
• Modulating sulfatide levels presents a potential therapeutic strategy for reducing Aβ pathology in AD.